

Financial Tear Sheet

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$10.65
Change (%)	▼ 0.15 (1.39%)
Volume	1,317,256
52 Week Low	\$9.85
Market Cap	\$336,498,987
Rolling EPS	-3.09
PE Ratio	N/A

Shares Outstanding 31,596,149

Data as of 06/22/18 4:00 p.m. ET



Recent Paratek Pharmaceuticals News & Events

06/20/18 - 9:07 a.m.

Paratek Announces FDA Advisory Committee Date for Omadacycline

There are currently no events scheduled.

06/11/18 - 8:00 a.m.

Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline in Treating Drug Resistant S. aureus at ASM Microbe 2018

06/07/18 - 4:05 p.m.

Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological

SEC Filings

Filing Date	Form
06/18/18	8-K
05/09/18	S-8
05/09/18	10-Q
05/02/18	4

Management

Michael F. Bigham	Chief Executive Officer and Chairman of the Board
Evan Loh, M.D.	President, Chief Operating Officer and Chief Medical Officer
Douglas W. Pagán	Chief Financial Officer
Adam Woodrow	Chief Commercial Officer
William Haskel	General Counsel and Corporate Secretary
Randy Brenner	Senior Vice President - Regulatory, Quality and Technical Operations
Regina Paglia	Senior Vice President - Human Resources
Evan Tzanis	Chief Development Officer

Jason Burdette	Vice President - Technical Operations
Jeanne Jew	Senior Vice President - Business Development
Raj Padmanabhan	Vice President - Information Technology
Susan Perkins, J.D.	Vice President - Intellectual Property
Christine R. Coyne, MBA	Vice President - Marketing
Sarah Higgins	Vice President - Controller
Paul McGovern, M.D.	Vice President - Clinical and Medical Affairs
Steve Sandor, MBA, J.D.	Vice President - Market Access and Trade
Judith N. Steenbergen, PhD	Vice President, Medical Strategy and Communications

Data provided by Nasdaq. Minimum 15 minutes delayed.